首页>
中文期刊>
《海南医科大学学报(英文版)》
>Research progress on intervention of traditional Chinese medicine on myocardial glucose and lipid metabolism in heart failure
Research progress on intervention of traditional Chinese medicine on myocardial glucose and lipid metabolism in heart failure
Disorder of energy metabolism is a major pathological change in the progression of heart failure.This process leads to insufficient myocardial energy and further aggravates cardiac dysfunction.Disorders of metabolic substrate utilization,mainly glucose and fatty acids,play an important role in this process.Research over the years has shown that some traditional Chinese medicines or compound prescriptions whose main role is to replenish qi and warm yang have good effects in regulating energy metabolism disorders.It has been found that some active ingredients in traditional Chinese medicine can regulate the uptake and utilization of myocardial cell metabolic substrate,so that the metabolism of myocardial cells can be adjusted in a direction that is beneficial to the body under hypoxic conditions,increasing the overall energy supply of the myocardium and improving heart function.This article reviewed the research of traditional Chinese medicine intervention on glucose and lipid metabolism of heart failure myocardial cells,and preliminarily summarizes the law and mechanism of traditional Chinese medicine intervention in heart failure myocardial glucose and fatty acid metabolism,hoping to provide clues for energy metabolism therapy research from the perspective of traditional Chinese medicine.
展开▼
机译：Yang Nianqun, Zaizao Bingren: Zhong Xi Yi Chongtu Xia De Kongjian Zhengzhi, 1832-1985 [Remaking "Patients": Politics of Space in the Conflicts between Traditional Chinese Medicine and Western Medicine, 1832-1985]
机译：Angela Ki-che Leung, Miandui jibing: Chuantong zhongguo shehui de yiliao guannian yu zuzhi 面对疾病:传统中国社会 的医疗观念与组织[In the Face of Disease: Concepts and Institutions of Medicine in Traditional Chinese Society]
机译：Trandolapril is a suitable choice for hypertonics with metabolic syndrome or with the risk of diabetes development and patients with heart failure after myocardial infarction
